anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

195,961-196,020 of 319,975

filter-aware
22
Membership Collective Group | Results Presentation Deck | 29 slidesMembership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
23
This slide provides accounting and operational definitions for various revenue streams.Membership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
24
This slide provides a glossary of financial and operational KPIs.Membership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
25
Financial data presented in thousands, except for per share data.Membership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
26
Financial statement data presented in thousands.Membership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
27
Financial statement page showing cash flow movements for two periods.Membership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
28
Contains three distinct financial reconciliation tables for the 13 weeks ending Oct 2, 2022 and Oct 3, 2021.Membership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
29
The table shows debt components, cash, and restricted cash to arrive at Net Debt, including percentage changes in actuals and constant currency.Membership Collective Group | Results Presentation Deck | 29 slides · Membership Collective Group
Deck Investor relations Beat · What Could Be1 hit
01
Slide 1
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
02
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
03
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
04
The slide uses a stylized wireframe human body to illustrate the systemic presence of iNKT cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
05
The slide uses a simple linear process flow to explain the manufacturing and administration of off-the-shelf cell therapies.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
06
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
07
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
08
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
09
Source: Rahib et al, JAMA Net 2021Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
10
Uses a temple pillar metaphor to represent the evolution of cancer treatment options.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Problem Statement1 hit
11
Source: Collisson et al, Nat Can Rev 2019Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
12
The diagram contrasts the state of T cell inhibition (left) with T cell activation (right) via therapeutic antibodies.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
13
Kaplan-Meier curve showing progression-free survival over 48 months.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
14
Source: Renouf at al, Nat Com 2022. Includes Kaplan-Meier curves (A, B), Forest plot (C), and stacked bar chart of response rates (D).Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
15
Source: Weber et al, Cell 2020Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
16
Data from Munshi et al, NEJM 2021.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
17
The slide uses a process diagram to illustrate the CAR T cell lifecycle and the microenvironment, followed by a table mapping obstacles to solutions.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Loop · Logic Chain1 hit
18
The slide uses a biological process diagram to explain the therapeutic mechanism.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
19
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
20
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
21
The diagram uses a hub-and-spoke model to show iNKT cells at the center modulating innate (Dendritic, Macrophage, NK) and adaptive (T, B) cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
22
The slide uses a biological process diagram to explain the mechanism of action for iNKT cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Proposed SolutionLoop · Logic Chain1 hit
23
Data presented as Kaplan-Meier survival curves and tumor growth kinetics/bar charts.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
24
The diagram depicts a biological process flow involving iNKT cells, DCs, MDSCs, and inflammatory monocytes.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
25
The table uses checkmarks, crosses, and question marks to indicate performance/capability across different cell types.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
26
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
27
The slide presents clinical efficacy metrics (ORR, SD, mOS) and safety profile for iNKT cell therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
28
The data shows a clear trend where the combination of iNKT activator + Fc enhanced CTLA-4 + PD-1 (Group F) results in the lowest number of metastases.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
29
The slide uses a process flow diagram to show trial progression and a list-based structure for clinical endpoints.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
30
The table displays patient characteristics (age, sex) and disposition (early discontinuation, death, progression) for three distinct dosing groups and the total population.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
31
The chart displays patient outcomes over time, with dots indicating progression and bars indicating stable disease.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
32
Includes a table of adverse events, box plots for cytokines (IL-1b, IL-6, CRP), and a longitudinal line chart for IFNy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
33
The slide uses a staircase diagram to represent dose escalation levels.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
34
The slide presents a patient cohort table and a specific case study (Patient 6) showing M-spike protein and plasma cell levels over time.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
35
The slide presents clinical trial safety data including a table of adverse events and dot plots for inflammatory markers.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
36
Includes references to SITC #372 and NCT05108623.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
37
Includes abstract number 372.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
38
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
39
The slide uses a three-column layout to present distinct biological mechanisms supported by experimental data (line and bar charts).Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
40
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
41
Illustrates the mechanism of action for two distinct therapeutic modalities.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
42
The diagram illustrates the interaction between iNKT cells and tumor cells/immune cells via various receptors (CAR, iTCR, NKG2D, DNAM1).Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
43
The slide uses a biological process diagram to explain the mechanism of action of the CARDIS platform.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
44
The slide uses a funnel metaphor to show the screening and selection process.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
45
The slide uses a funnel metaphor to show the progression from synthetic phage libraries to final candidates.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
46
The slide uses a bar chart to show the distribution of clones, with a red circle highlighting the 'binders specific activators' category.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
47
The diagram shows the interaction between tumor cell receptors and iNKT cell receptors, including the secretion of IL15.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
48
Includes abstract number 358.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
49
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
50
The slide uses a Kaplan-Meier survival plot and longitudinal imaging to demonstrate therapeutic efficacy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
51
The slide uses fluorescence microscopy images and an area chart to demonstrate the efficacy of the therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
52
Includes abstract number 322.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit